Blog Archive

Saturday, May 24, 2014

Introducing Emergent BioSolutions


A few weeks ago, I shared my admiration for my colleague John Taylor, co-founder of the Coalition for Hemophilia B, with information about his role in developing treatment options for people with hemophilia and how that work is continuing with Emergent BioSolutions. I had the chance to meet the Emergent team at the World Federation of Hemophilia Congress in Melbourne this month and see for myself their passion for this community. I wanted to share with you how Emergent BioSolutions plans to provide a different kind of patient experience, so I asked them to share their story with us. 

At Emergent BioSolutions, we know that living with hemophilia B is an ever-changing experience. It has been a goal of ours to bring a different kind of experience to hemophilia B patients and families, and we are excited to introduce ourselves to you face to face and learn your personal stories. 
 
Emergent BioSolutions’ history has been one of innovation and growth, while staying true to our mission—to protect and enhance life.  As a global specialty pharmaceutical company, Emergent offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. From our beginnings as a private company with a single location in Lansing, Michigan, Emergent has grown into a thriving public company, with sites around the world and several products contained in the US Strategic National Stockpile. Knowing that the government relies on us for these essential products, we take the responsibility seriously and are proud to participate in helping protect this great country.

Our role as a major supplier to the US government has enabled our expansion into other therapeutic areas. In 2014 we acquired Cangene Corporation, bringing to Emergent over 45 years of experience in providing specialized therapies for the treatment of rare diseases and blood disorders.

Emergent BioSolutions is a different type of company, and we are determined to make a difference for people with hemophilia B and those who care for them. Our long-standing history of providing treatments for people with rare conditions is matched by our focus on improving the lives of these small patient populations. Our continued efforts in these areas have led us to develop the kind of experience necessary to make a positive impact on the hemophilia B community.

Over the course of the last year, Emergent has been passionate about meeting the hemophilia B community and learning all of the incredible stories that families have kindly shared with us. At the National Hemophilia Foundation Annual Meeting in Anaheim, our booth featured a “Make Your Mark” experience, which allowed patients to create a personal hemophilia thumbprint that told their unique story.  

Just recently, Emergent traveled to Australia to participate in the WFH World Congress—the largest international meeting for the global bleeding disorders community. There, we learned more about the needs of patients and their families to help us make a difference in the lives of those in the hemophilia B community.

We have been so touched and impressed by all of the personal stories that patients and their families shared with us this year. We are excited to carry on the important work started by John Taylor, and we are proud to continue bringing his vision to life.

You can learn more about Emergent BioSolutions and register for updates at www.ebsi.com/hemophiliab.

No comments :

 
Bayer